As of Friday close, Royalty Pharma plc’s (NASDAQ:RPRX) stock was up $0.07, moving up 0.27 percent to $26.33. The average number of shares traded per day over the past five days has been 3,044,740 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.80 fall in that time frame. In the last twenty days, the average volume was 2,575,365, while in the previous 50 days, it was 2,115,828.
Since last month, RPRX stock retreated -11.29%. Shares of the company fell to $25.92 on 09/21/23, the lowest level in the past month. A 52-week high of $44.47 was reached on 01/03/23 after having rallying from a 52-week low of $25.92. Since the beginning of this year, RPRX’s stock price has dropped by -33.38% or -$13.19, and marked a new high 1 time. However, the stock has declined by -40.79% since its 52-week high.
RPRX stock investors should be aware that Royalty Pharma plc (RPRX) stock had its last reported insider trading activity 44 days ago on Aug 10. Coyne Terrance P., the EVP & CFO of the company, disposed of 37,500 shares for $30.75 on Aug 10. It resulted in a $1,153,091 divestment by the insider. Coyne Terrance P. sold 37,500 shares at an average price of $30.72 on Aug 09. The insider now owns 827,500 shares following the transaction. On Jul 13, EVP & CFO Coyne Terrance P. sold 37,500 shares at $30.93 apiece. The transaction was valued at $1,159,958.
Valuation Metrics
Right now, Royalty Pharma plc (RPRX) has a P/E ratio of about 46.85. The stock’s beta is 0.44. Besides these, the trailing price-to-sales (P/S) ratio of 6.86, the price-to-book (PB) ratio of 1.89, and the price-to-cash flow ratio of 31.05 may also be considered.
The latest dividend of $0.20 per share was paid out, remained unchanged from last year’s $0.20. On Monday January 9 2023, a $0.01 dividend increase was announced.
Financial Health
In the three months ended June 29, Royalty Pharma plc’s quick ratio stood at 2.50, while its current ratio was 2.50, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.98, and the total debt-to-equity ratio was 1.13. In the year ended June 29, operating margins totaled 18.50%. Based on annual data, RPRX earned $1.93 billion in gross profit and brought in $2.24 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 2.40%. Return on equity (ROE) for the past 12 months was 4.20%.
In Royalty Pharma plc’s quarter-end financial report for June 29, it reported total debt of $6.13 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. RPRX’s revenue rose 0.42% to $683.97 million during the quarter, while net income inched up to $538.2 million. While analysts expected Royalty Pharma plc to report $0.81 quarterly earnings, the actual figure was $0.84 per share, beating the consensus estimate by 3.70%. During the quarter, the company generated $254.16 million in EBITDA. The liabilities of Royalty Pharma plc were 7.31 billion at the end of its most recent quarter ended June 29, and its total debt was $7.13 billion. The value of shareholders’ equity is $601.82 million.
Technical Picture
This quick technical analysis looks at Royalty Pharma plc’s (RPRX) price momentum. With a historical volatility rate of 21.37%, the RSI 9-day stood at 16.07% on 22 September.
With respect to its five-day moving average, the current Royalty Pharma plc price is down by -6.40% percent or -$1.80. At present, RPRX shares trade -10.93% below its 20-day simple moving average and -25.47% percent below its 100-day simple moving average. However, the stock is currently trading approximately -14.26% below its SMA50 and -38.78% below its SMA200.
Stochastic coefficient K was 6.91% and Stochastic coefficient D was 6.02%, while ATR was 0.68. Given the Stochastic reading of 9.40% for the 14-day period, the RSI (14) reading has been calculated as 21.39%. As of today, the MACD Oscillator reading stands at -1.13, while the 14-day reading stands at -1.60.
Analyst Ratings
Royalty Pharma plc (RPRX) has been rated Buy by analysts. According to 0 brokerage firms, RPRX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Royalty Pharma plc stock as buy, with 7 recommending it as overweight.
With a median target price of $49.00, the current consensus forecast for the stock is $40.00 – $60.00. Based on these forecasts, analysts predict Royalty Pharma plc (RPRX) will achieve an average price target of $48.43.
